Cellular and Oxidative Mechanisms Associated with Interleukin-6 Signaling in the Vasculature
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Reactive oxygen species, particularly superoxide, promote endothelial dysfunction and alterations in vascular structure. It is increasingly recognized that inflammatory cytokines, such as interleukin-6 (IL-6), contribute to endothelial dysfunction and vascular hypertrophy and fibrosis. IL-6 is increased in a number of cardiovascular diseases, including hypertension. IL-6 is also associated with a higher incidence of future cardiovascular events and all-cause mortality. Both immune and vascular cells produce IL-6 in response to a number of stimuli, such as angiotensin II. The vasculature is responsive to IL-6 produced from vascular and non-vascular sources via classical IL-6 signaling involving a membrane-bound IL-6 receptor (IL-6R) and membrane-bound gp130 via Jak/STAT as well as SHP2-dependent signaling pathways. IL-6 signaling is unique because it can also occur via a soluble IL-6 receptor (sIL-6R) which allows for IL-6 signaling in tissues that do not normally express IL-6R through a process referred to as IL-6 trans-signaling. IL-6 signaling mediates a vast array of effects in the vascular wall, including endothelial activation, vascular permeability, immune cell recruitment, endothelial dysfunction, as well as vascular hypertrophy and fibrosis. Many of the effects of IL-6 on vascular function and structure are representative of loss or reductions in nitric oxide (NO) bioavailability. IL-6 has direct effects on endothelial nitric oxide synthase activity and expression as well as increasing vascular superoxide, which rapidly inactivates NO thereby limiting NO bioavailability. The goal of this review is to highlight both the cellular and oxidative mechanisms associated with IL-6-signaling in the vascular wall in general, in hypertension, and in response to angiotensin II.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 2×
“A third mechanism of IL-6 signaling inhibition involves protein inhibitor of activated STAT-3 (PIAS3), which binds elements in IL-6 target genes thereby inhibiting phosphorylated STAT3/DNA interaction and gene transcription [142].”
BackgroundThe pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.
Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., & Alexander, R. W. (1994) · Circulation Research · doi:10.1161/01.res.74.6.1141 · Cited by 2,735
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511 · cited 6×
“serve as docking sites for recruitment of STAT molecules, results in phosphorylation and dimerization of phosphorylated STAT [78,124].”
BackgroundInfluentialHypertension in mice lacking the gene for endothelial nitric oxide synthase
Huang, P. L., Huang, Z., Mashimo, H., Bloch, K. D., Moskowitz, M. A., Bevan, J. A., & Fishman, M. C. (1995) · Nature · doi:10.1038/377239a0 · Cited by 2,070
Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets
Drummond, G. R., Selemidis, S., Griendling, K. K., & Sobey, C. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3403 · Cited by 899
SOCS3 negatively regulates IL-6 signaling in vivo
Croker, B. A., Krebs, D. L., Zhang, J.-G., Wormald, S., Willson, T. A., Stanley, E. G., Robb, L., Greenhalgh, C. J., Förster, I., Clausen, B. E., et al. (2003) · Nature Immunology · doi:10.1038/ni931 · Cited by 840
IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation
Kaplanski, G. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(02)00013-3 · Cited by 811 · cited 9×
“Binding of IL-6 to sIL-6R and subsequent binding to tissue bound gp130 IL-6/sIL-6R signaling transduction proceeds in a similar manner as classical IL-6R signaling (Figur 2). sIL-6R has the added advant ge that it als serves to bind circulating IL-6 thereby greatly extending the half-lif of IL-6 [130]. sIL-6R also reg…”
BackgroundInfluentialHurst, S. M., Wilkinson, T. S., McLoughlin, R. M., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Fuller, G. M., Topley, N., & Jones, S. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00151-0 · Cited by 811 · cited 1×
“IL-6 mediated increases in adhesion molecule expression is thought to play an important role in the early phase of inflammation where lymphocytes such as neutrophils predominate, whereas in latter phases infiltration of monocytic cells, such as macrophages, predominate [67].”
BackgroundInterleukin-6 and its receptors: a highly regulated and dynamic system
Wolf, J., Rose-John, S., & Garbers, C. (2014) · Cytokine · doi:10.1016/j.cyto.2014.05.024 · Cited by 618 · cited 1×
“Such a dual signaling pathway has been proposed to endow vascular and immune cells with specific cellular responses to various IL-6-producing stimuli [146].”
BackgroundIgG1 plasmacytosis in interleukin 6 transgenic mice
Suematsu, S., Matsuda, T., Aozasa, K., Akira, S., Nakano, N., Ohno, S., Miyazaki, J., Yamamura, K., Hirano, T., & Kishimoto, T. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7547 · Cited by 586 · cited 2×
“IL-6-transgenic mice are characterized by elevated plasma IL-6 levels as well as a number of outward phenotypes, including pulmonary hypertension [180,181].”
BackgroundLin, Z.-Q., Kondo, T., Ishida, Y., Takayasu, T., & Mukaida, N. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0802397 · Cited by 585 · cited 1×
“Interestingly, IL-6-deficient mice are characterized by impaired wound healing, a process that involves fibroblasts, TGF-β signaling, and extracellular matrix remodeling [169].”
BackgroundFernandez-Real, J.-M., Vayreda, M., Richart, C., Gutierrez, C., Broch, M., Vendrell, J., & Ricart, W. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7305 · Cited by 567
NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium
Mohazzab, K. M., Kaminski, P. M., & Wolin, M. S. (1994) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1994.266.6.h2568 · Cited by 536
Nox1 Is Involved in Angiotensin II–Mediated Hypertension: A Study in Nox1-Deficient Mice
Matsuno, K., Yamada, H., Iwata, K., Jin, D., Katsuyama, M., Matsuki, M., Takai, S., Yamanishi, K., Miyazaki, M., Matsubara, H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.573709 · Cited by 470
Schmitz, J., Weissenbach, M., Haan, S., Heinrich, P. C., & Schaper, F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.17.12848 · Cited by 388
Han, Y., Runge, M. S., & Brasier, A. R. (1999) · Circulation Research · doi:10.1161/01.res.84.6.695 · Cited by 377
Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation
KOFLER, S., NICKEL, T., & WEIS, M. (2005) · Clinical Science · doi:10.1042/cs20040174 · Cited by 353
Decreased blood pressure in NOX1‐deficient mice
Gavazzi, G., Banfi, B., Deffert, C., Fiette, L., Schappi, M., Herrmann, F., & Krause, K.-H. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.049 · Cited by 321
eNOS Uncoupling in Cardiovascular Diseases - the Role of Oxidative Stress and Inflammation
Karbach, S., Wenzel, P., Waisman, A., Munzel, T., & Daiber, A. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660748 · Cited by 307
Sano, M., Fukuda, K., Sato, T., Kawaguchi, H., Suematsu, M., Matsuda, S., Koyasu, S., Matsui, H., Yamauchi-Takihara, K., Harada, M., et al. (2001) · Circulation Research · doi:10.1161/hh2001.098873 · Cited by 298 · cited 4×
“Both candesartan, an AT1R antagonist and DPI an inhibitor of flavin-containing enzymes, including NADPH oxidase is associated with reduction in angiotensin II-induced fibrosis [61].”
BackgroundInfluentialGarbers, C., Jänner, N., Chalaris, A., Moss, M. L., Floss, D. M., Meyer, D., Koch-Nolte, F., Rose-John, S., & Scheller, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229393 · Cited by 201 · cited 1×
“sIL-6R derived primarily from cleavage of membrane-bound IL-6R through ADAM17 and ADAM10 activation and to a lesser degree through alternate IL-6R splice variant [128,129].”
BackgroundExtracellular matrix alterations in hypertensive vascular remodeling
Lemarié, C. A., Tharaux, P.-L., & Lehoux, S. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.09.018 · Cited by 192
Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo.
Schöbitz, B., Pezeshki, G., Pohl, T., Hemmann, U., Heinrich, P. C., Holsboer, F., & Reul, J. M. H. M. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.8.7768358 · Cited by 159
Hsich, E., Segal, B. H., Pagano, P. J., Rey, F. E., Paigen, B., Deleonardis, J., Hoyt, R. F., Holland, S. M., & Finkel, T. (2000) · Circulation · doi:10.1161/01.cir.101.11.1234 · Cited by 158
Johnson, A. W., Kinzenbaw, D. A., Modrick, M. L., & Faraci, F. M. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.00299 · Cited by 63
Cited by
Jin, Y., Ji, W., Yang, H., Chen, S., Zhang, W., & Duan, G. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00454-7 · Cited by 399
Immune and inflammatory mechanisms in hypertension
Guzik, T. J., Nosalski, R., Maffia, P., & Drummond, G. R. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00964-1 · Cited by 315
Immune Dysregulation in Autism Spectrum Disorder: What Do We Know about It?
Robinson-Agramonte, M. D. L. A., Noris García, E., Fraga Guerra, J., Vega Hurtado, Y., Antonucci, N., Semprún-Hernández, N., Schultz, S., & Siniscalco, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063033 · Cited by 176
Serum Levels of the IL-6 Family of Cytokines Predict Prognosis in Renal Cell Carcinoma (RCC)
Gudbrandsdottir, G., Aarstad, H. H., Bostad, L., Hjelle, K. M., Aarstad, H. J., Bruserud, Ø., Tvedt, T. H. A., & Beisland, C. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02655-z · Cited by 35
“IL-6 is elevated in hypertension, as well as being associated with a higher incidence of future cardiovascular events and mortality [33].”
BackgroundVascular Senescence: A Potential Bridge Between Physiological Aging and Neurogenic Decline
Rojas-Vázquez, S., Blasco-Chamarro, L., López-Fabuel, I., Martínez-Máñez, R., & Fariñas, I. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666881 · Cited by 15
Metadata
- Authors
- Didion, S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-11-29
- Volume
- 18
- Issue
- 12
- Pages
- 2563
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2775702351
- Cited by
- 228
- References
- 26
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.